1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Revenue of 180 Life Sciences Corp. (ATNF)
Revenue in 2023 (TTM): $
According to 180 Life Sciences Corp.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of 180 Life Sciences Corp.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-105,675 | $-13,371,824 | $-22,284,525 | $-19,935,112 |
| 2022 | $ | $-109,004 | $-17,788,961 | $-39,669,008 | $-38,726,259 |
| 2021 | $ | $-116,297 | $-15,531,055 | $-20,347,852 | $-20,324,648 |
| 2020 | $ | $-125,333 | $-5,522,779 | $-10,904,484 | $-12,006,760 |
| 2019 | $ | $-72,244 | $-20,791,042 | $-25,403,542 | $-25,394,046 |
| 2018 | $ | $ | $-8,720,769 | $-14,495,440 | $-14,495,440 |
| 2017 | $ | $ | $-343,884 | $319.13 K | $123.76 K |